Fulltext

Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group

Italiano, A. ; Penel, N. ; Robin, Y.-M ; Bui, B. ; Le Cesne, A. ; Piperno-Neumann, S. ; Tubiana-Hulin, M. ; Bompas, E. ; Chevreau, C. ; Isambert, N. ; Leyvraz, S. ; du Chatelard, P. P. ; Thyss, A. ; Coindre, J.-M ; Blay, J.-Y

In: Annals of Oncology, 2008, vol. 20, no. 3, p. 425-430

Aggiungi alla tua lista
    Titre
    • Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group
    Auteur
    • Italiano, A.. Department of Medical Oncology, Institut Bergonié, Bordeaux
    • Penel, N.. Department of Medical Oncology, Centre Oscar Lambret, Lille
    • Robin, Y.-M. Department of Pathology, Centre Oscar Lambret, Lille
    • Bui, B.. Department of Medical Oncology, Institut Bergonié, Bordeaux
    • Le Cesne, A.. Department of Medicine, Institut Gustave Roussy, Villejuif
    • Piperno-Neumann, S.. Department of Medical Oncology, Institut Curie, Paris
    • Tubiana-Hulin, M.. Department of Medical Oncology, Centre René Huguenin, Saint-Cloud
    • Bompas, E.. Department of Medical Oncology, Centre René Gauducheau, Nantes
    • Chevreau, C.. Department of Medical Oncology, Institut Claudius Regaud, Toulouse
    • Isambert, N.. Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
    • Leyvraz, S.. Department of Medical Oncology, University Hospital Centre Vaudois, Lausanne, Switzerland
    • du Chatelard, P. P.. Department of Radiotherapy, Centre Paul Papin, Angers
    • Thyss, A.. Department of Medical Oncology, Centre Antoine-Lacassagne, Nice
    • Coindre, J.-M. Department of Pathology, Institut Bergonié, Bordeaux
    • Blay, J.-Y. Departement of Medical Oncology, Hôpital Edouard Herriot, Lyon
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Annals of Oncology, 2008, vol. 20, no. 3, p. 425-430. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:297097
    Summary
    Background: There are only scarce data about the benefit of adjunctive chemotherapy in patients with localized synovial sarcoma (SS). Patients and methods: Data from 237 SS patients recorded in the database of the French Sarcoma Group were retrospectively analyzed. The respective impact of radiotherapy, neo-adjuvant chemotherapy and adjuvant chemotherapy on overall survival (OS), local recurrence-free survival (LRFS) and distant recurrence-free survival (DRFS) were assessed after adjustment to prognostic factors. Results: The median follow-up was 58 months (range 1-321). Adjuvant, neo-adjuvant chemotherapy and postoperative radiotherapy were administered in 112, 45 and 181 cases, respectively. In all, 59% of patients treated with chemotherapy received an ifosfamide-containing regimen. The 5-year OS, LRFS and DRFS rates were 64.0%, 70% and 57%, respectively. On multivariate analysis, age >35 years old, grade 3 and not-R0 margins were highly significant independent predictors of worse OS. After adjustment to prognostic factors, radiotherapy significantly improved LRFS but not DRFS or OS. Neither neo-adjuvant nor adjuvant chemotherapy had significant impact on OS, LRFS or DRFS. Conclusion: As for other high-grade soft-tissue sarcomas, well-planned wide surgical excision with adjuvant radiotherapy remains the cornerstone of treatment for SS. Neo-adjuvant or adjuvant chemotherapy should not be delivered outside a clinical trial setting